每周股票复盘：天域生物（603717）前三季净利亏损161万

Core Insights - Tianyu Biological (603717) reported a closing price of 9.16 yuan as of October 31, 2025, reflecting a 1.55% increase from the previous week [1] - The company experienced a significant decline in revenue and net profit for the first three quarters of 2025, with a revenue of 536 million yuan, down 14.23% year-on-year [2] - The actual controller of the company changed to Luo Weiguo after the termination of the concerted action relationship with Shi Dongwei [3] Shareholder Changes - As of September 30, 2025, the number of shareholders increased to 21,700, a rise of 7.49% compared to June 30, 2025 [4] - The average number of shares held per shareholder decreased from 14,400 to 13,400 shares, with an average holding value of 118,400 yuan [1] Performance Disclosure - For the first three quarters of 2025, the company reported a net profit attributable to shareholders of -1.61 million yuan, a year-on-year decline of 152.22% [2] - The third quarter alone saw a revenue of 123 million yuan, down 38.69% year-on-year, with a net profit of -12.43 million yuan, a staggering decline of 7912.82% [2] - The company's debt ratio stood at 76.41%, with a gross profit margin of 13.16% [2] Company Announcements - The company plans to issue up to 71.03 million shares to Shanghai Daoyun Asset Management Co., Ltd., controlled by the new actual controller, to raise no more than 465 million yuan for working capital and debt repayment [3] - The board approved the continuation of commodity futures hedging activities, with a maximum margin of 50 million yuan and a contract value of up to 255 million yuan, valid from October 31, 2025, to October 30, 2026 [3]